Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 5/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 5/20 | 0.33 |
| ▸ | BRAF | P15056 | 4/20 | 0.33 |
| ▸ | MTOR | P42345 | 2/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL158598 | 0.80 | JAK3 (0.40) | MAP4K1LRRK2NTRK1 | |
| SCHEMBL160097 | 0.75 | ENPP3 (0.34) | — | |
| SCHEMBL161285 | 0.73 | PDK2 (0.33) | — | |
| SCHEMBL161917 | 0.73 | RPS6KB1 (0.41) | — | |
| SCHEMBL160543 | 0.72 | SLC22A12 (0.33) | — | |
| SCHEMBL162750 | 0.72 | GUCY1B2 (0.30) | — | |
| SCHEMBL162931 | 0.72 | MAP4K4 (0.38) | — | |
| SCHEMBL163370 | 0.71 | GLO1 (0.38) | — | |
| SCHEMBL158566 | 0.71 | BDKRB1 (0.36) | — | |
| SCHEMBL164201 | 0.66 | GRM5 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633207-B2 | Quinazoline compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2611789-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030948-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20120053174-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053174-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | JAK3, JAK2, TYK2 | MAP4K1 75/4885LRRK2 395/4885RAF1 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.